To investigate the putative modifying effect of dual antiplatelet therapy (DAPT) use on the incidence of stent thrombosis at 3 years in patients randomized to Endeavor zotarolimus-eluting stent (E-ZES) or Cypher sirolimus-eluting stent (C-SES).
Introduction
The importance of dual antiplatelet therapy (DAPT) to prevent in-stent thrombotic events in patients implanted with a drug-eluting stent (DES) has been widely reported. 1 -3 Interruption of DAPT is also a major independent predictor of stent thrombosis, 4 underscor-
The Patient Related OuTcomes with Endeavor vs. Cypher stenting Trial (PROTECT) 5 was designed as a superiority trial comparing the incidence of stent thrombosis in a broad population of patients and involving two widely used DES with different potency profiles and nearly opposite healing characteristics: the Endeavor zotarolimuseluting stent (E-ZES; Medtronic CardioVascular) and the Cypher sirolimus-eluting stent (C-SES; Cordis, Johnson & Johnson). 6, 7 Both devices prevent the occurrence of restenosis yet have different antiproliferative potencies due to drug, polymer, and drug-release characteristics. 8 Therefore, the key design element of PROTECT was the selection of two DES systems with contrasting site-specific vascular healing responses, with E-ZES more closely mirroring the healing response following bare-metal stent implantation. 6, 7 In PROTECT, the primary outcome of definite or probable stent thrombosis at 3 years did not differ between E-ZES and C-SES [1.42% (predicted 1.5%) vs. 1.79% (predicted 2.5%); log-rank P ¼ 0.22], respectively. 9 During the period from 1 to 3 years when the use of DAPT was low, however, a significant 0.75% difference emerged in the incidence of stent thrombosis (E-ZES 0.32% vs. C-SES 1.07%; log-rank P , 0.0001). We hypothesized that DAPT use influenced the rate of stent thrombosis to a different extent, depending upon the type of implanted DES.
Methods
PROTECT is a two-arm, multinational superiority trial, with a prospective randomized open-label blinded-endpoints design. 5 The trial involved 196 centres in 36 countries across five continents. Patients were randomized 1 : 1 to E-ZES or C-SES and mandated to undergo an electrocardiogram at 3-year follow-up. Source documentation of all events was 100% monitored. Other data monitoring was performed in 30% of randomly selected patients at all centres. Patients provided informed consent to participate. The protocol was approved by the institutional ethical committee and/or centralized national ethical board according to the rules specific to the country. Stent thrombosis (definite or probable) was defined according to the Academic Research Consortium definitions. 10 In accordance with the main results paper, 9 the composite of definite or probable stent thrombosis at 3 years was the primary endpoint and definite stent thrombosis the secondary endpoint. Dual antiplatelet therapy was defined as the combination of aspirin plus clopidogrel or ticlopidine (both pro-drugs metabolized in the liver) and no DAPT ('off-DAPT') was defined as either single antiplatelet (aspirin or clopidogrel/ticlopidine) or no antiplatelet therapy.
Statistical methods
We systematically analysed if (and to what extent) DAPT use modified the effect of stent type on the primary and secondary endpoints. Follow-up visits were scheduled up to 36 months, and information on actual DAPT use was collected. We calculated cumulative patient-years of follow-up in relation to DAPT exposure. The 'on'/'off' DAPT status at each visit determined the status for the period between this and the next visit. Thus, an individual could potentially contribute to patient-years 'on' as well as 'off' DAPT, and any treatment change was taken into account. We report the number of patients who reached a study endpoint relative to the cumulative patient-years of follow-up in relation to DAPT exposure (i.e. DAPT-specific incidence rates). We do not report multiple events per patient and follow-up time was not counted after a study endpoint was reached.
Univariate Cox proportional hazard regression models were fitted, with stent thrombosis as the outcome and stent treatment and DAPT use as the determinants. We defined DAPT use as a time-dependent covariate, in agreement with the definition described above. Multivariable Cox models were subsequently fitted, and the following variables were considered as potential covariates: age, medical history (diabetes mellitus, cigarette smoking, prior myocardial infarction, or stroke), serum creatinine, stent length and diameter, overlapping stents, lesion characteristics, assigned treatment (E-ZES vs. C-SES), and a timedependent covariate for DAPT. To avoid over-fitting the model, the number of covariates (i.e. the associated degrees of freedom) was limited to 1 for each 10 incident endpoints. Covariates with the lowest P-values in univariate analysis were selected. We then applied the backward-deletion model reduction strategy so that in the final model all covariates had a P-value ,0.15. The final multivariable model was enriched with the interaction term 'stent-treatment * DAPT' (as the time-dependent covariate).
P-values of ,0.05 were considered statistically significant and no formal adjustment was made for multiple testing. Analyses were performed using SAS, version 9.2.
Results
Between 21 May 2007 and 22 December 2008, 8791 patients were identified, of which 8709 provided consent and were eligible for inclusion: 4357 patients were randomized to E-ZES and 4352 to C-SES. Data for 8340 (95.8%) patients were available at 3-year follow-up.
The groups were similar in terms of their clinical characteristics. Lesion characteristics revealed more lesions treated in the main stem and in the right coronary as well as calcified lesion in the C-SES group; procedural characteristics revealed a greater number of stents per lesion and overlapping stents, and lower use of predilatation in the E-ZES group ( Table 1) .
Dual antiplatelet therapy and stent type as determinants of stent thrombosis
Incidence and incidence rate of stent thrombosis are shown in Table 2 . Adherence to DAPT at day 30 and at all follow-up intervals up to 3 years was similar in both groups ( Table 3 and Figures 1 and  2) . 'Off-DAPT' patients were evenly distributed among aspirin alone, thienopyridine alone, and no DAPT up to 3 years in both groups, with the exception of a slightly higher use of thienopyridine in the E-ZES group at 1 year ( Table 3) . Cumulative follow-up patientyears in the presence ('on-DAPT') or absence ('off-DAPT') of DAPT according to stent type were also similar ( Figure 1 and 2 subtables) .
A statistically significant heterogeneity was observed in treatment effect of stent type in relation to DAPT use for definite or probable stent thrombosis (P ¼ 0.0052) and for definite stent thrombosis (P ¼ 0.012). Figure 3 and Table 4 summarize the outcomes of the interaction between DAPT and stent type on the incidence of stent thrombosis. From the perspective of DAPT use, no significant DAPT effect was observed in E-ZES patients in terms of the incidence rate of stent thrombosis, whereas a significant effect was seen in C-SES patients. From the perspective of stent type, off-DAPT the incidence rate and incidence for both definitions of stent thrombosis at 3 years (1080 days) were lower with E-ZES than with C-SES ( Table 2 , 
Further determinants of stent thrombosis
Independent predictors of stent thrombosis ( Table 4) show a similar pattern to the univariate predictors ( Table 2 , Appendix 2), with diabetes mellitus, ≥1 stent ≤2.75 mm in diameter, and current smoking being strongly significant for both definitions of stent thrombosis.
Discussion
These data from PROTECT suggest that adherence to DAPT modifies the outcome of stent thrombosis to a greater extent after C-SES deployment than after E-ZES deployment, most likely due to differential healing characteristics. These findings suggest that DAPT use should be taken into consideration when interpreting the incidence of stent thrombosis in studies evaluating different DES.
Irrespective of the definition of stent thrombosis used (i.e. definite or probable or definite alone) a highly significant interaction was observed between DES type and DAPT use. From the perspective of stent type, this interaction revealed a higher incidence and incidence rate of stent thrombosis in the C-SES arm off-DAPT. Conversely, in patients on-DAPT, both stent types showed a similar incidence and incidence rate of stent thrombosis. This analysis did not evaluate a differentiated effect of either single antiplatelet vs. no antiplatelet therapy or different types of single antiplatelet therapies. From earlier literature one can assume that the less potent the antiplatelet regimen the higher the incidence of stent thrombosis. 11 Thus, the current analysis comparing the influence of a standard DAPT regimen with a pooled mix of single or no antiplatelet therapy may have attenuated the current findings between E-ZES and C-SES.
The risk assessment expressed as cumulative incidence rate shows a greater sensitivity to detect safety signals off-DAPT. Further, the cumulative incidence curves for definite/probable and definite stent thrombosis for E-ZES vs. C-SES start to separate at 18 months (540 days) and continue to diverge up to 1080 days. Conversely, while on-DAPT, the incidence curves of stent thrombosis for both stent types remain close, running almost parallel from 720 days onwards, revealing little sensitivity to detect stent-thrombosisrelated safety signals and thus having similar long-term stentthrombosis-related safety profiles. Thus, the incidence of stent thrombosis over time was distributed differentially according to DAPT-adherence pattern: off-DAPT the difference started to emerge after 18 months; on-DAPT both devices had a very similar incidence of (early and) very late stent thrombosis, but E-ZES had a numerically higher incidence of late stent thrombosis (. 30 days to 1 year). Pathophysiologically, a less DAPT-dependent mechanism seems to play a role in E-ZES late events and a more DAPT-dependent mechanism in C-SES very late events (.1 year), suggesting different mechanisms of stent occlusion (i.e. occlusive restenosis in the E-ZES group vs. thrombotic occlusion secondary to delayed healing and/or plaque rupture in the context of neo-atherosclerosis 12 in the C-SES group).
Because almost all the patients were on-DAPT during the first year, we looked at the period after 360 days (very late), when adherence started to drop ,80% and thus the cumulative follow-up patient-years off-DAPT started to increase substantially as did the rate of events. We found that 3350 cumulative patient-years off-DAPT per group would have provided the protocol-mandated statistical power of 90% 5 to reveal a coherent safety signal between the two stent systems according to the primary endpoint, representing slightly over 1.5 years.
From the perspective of DAPT use, patients randomized to E-ZES showed no significant DAPT effect on the incidence of stent thrombosis up to 3 years, whereas a significant effect could be demonstrated in the C-SES group. Therefore, the 'DAPT effect' is more apparent after deployment of the potent C-SES DES, inducing a longer-term altered healing response, and reflecting both a persistent in-stent pro-thrombotic environment and a likely need for prolonged antithrombotic administration. Not unexpectedly other strong univariate and multivariable predictors of stent thrombosis, which could guide tailoring DAPT duration on an individual basis, were also related-at least in part-to stent or vessel-healing properties. Patients with multiple characteristics that alter vessel recovery and favour persistency of a site-specific in-stent pro-thrombotic milieu are likely to need a more prolonged duration of DAPT. Of interest, in this context, the strongest criterion to pursue long-term thromboprotective DAPT was diabetes mellitus.
The strong interaction between the treatment modalities 'DES type' and 'DAPT use', an aspect linked to clinical trial methodology neglected thus far, may also be relevant when re-evaluating the literature on DES. The key points are the following:
First, the period off-DAPT shows a greater sensitivity to detect safety signals after DES deployment. Therefore, long-term followup (with sufficient events and patient-years) is essential to ensure sufficient off-DAPT time to detect a difference between DES types. This is particularly true in randomized trials in which DAPT duration is not mandated in the protocol, as demonstrated in the primary analysis from PROTECT. 9 When DAPT duration is mandated but DAPT use at follow-up is missing and a balanced use of DAPT among groups can be assumed, long-term follow-up remains essential to detect safety signals, as demonstrated in the 3-year follow-up of SORT OUT III-a trial similar by design to PROTECT, and using an administrative-guided clinical endpoint. 13 Not surprisingly, the first long-term safety signals became apparent in the very first trials in which duration of DAPT was defined and when physicians were not aware of the risk of late or very late thrombotic events. 14 -16 Second, high adherence to DAPT prevents a reliable evaluation of the safety profiles of stent systems as assessed by the incidence of stent thrombosis. Therefore, randomized trials with short follow-up (up to 1 year) and high adherence to DAPT over the study-period have limited validity to determine long-term safety profiles of study stents using stent thrombosis as a criterion. 17 -25 One should not neglect, however, the impact of stent thrombosis secondary to occlusive restenosis 23 -25 -a less 'DAPT-dependent' phenomenon-as a confounding factor during the first year. Third, apparent differences in the safety profiles of DES may be due to imbalances in use of DAPT across study arms. Therefore, clinical evaluations (e.g. in sequential registries or meta-analyses) of DES systems with different adherence to DAPT or that do not factor in DAPT effect will be limited in terms of their ability to evaluate DES safety profiles using the stent-thrombosis criterion. 26, 27 Fourth, the healing characteristics associated with stent systems influence the thromboprotective efficacy of DAPT, as shown in this analysis. Therefore, pooling data from different DES types 28 -33 or DAPT regimens, 34 or determination of a generalized optimal duration of DAPT after DES deployment, 28, 30, 32 without taking into account the specific biological attributes of each stent system will not provide a clinically valuable message. Conversely, the evaluation of a specific stent system for different durations of DAPT is clinically meaningful, but generalization of the stent-specific finding to other DES types should be avoided. 35, 36 To put this analysis of the 3-year results of PROTECT into perspective, we searched Medline for randomized trials that analysed the interaction of DES type and DAPT use in relation to clinical events. We found PRODIGY, 37 which explored prospectively in 2013 patients randomized in a 4-by-2 design to four stent types (baremetal, zotarolimus-eluting, paclitaxel-eluting, and everolimus-eluting) and two different durations of DAPT (6 vs. 24 months). The primary endpoint was a composite of death, myocardial infarction, or cerebrovascular accident; the secondary endpoint was stent thrombosis. The authors observed heterogeneity across stent types driven by: an improved primary endpoint as well as a lower incidence of stent thrombosis after short-term DAPT in the zotarolimus arm (corresponding to E-ZES in PROTECT); and a higher incidence of stent thrombosis after short-term DAPT in the paclitaxel-eluting arm. They concluded, similar to the current analysis, that the optimal duration of DAPT may be stent-specific. However, no satisfactory answer to the pathophysiological mechanisms underlying this observation could be given. An interaction between stent type and DAPT is likely to be present and to persist in any stent system until vascular recovery has been achieved; therefore this interaction will be clinically more important with stent systems associated with a more delayed vascular healing and/or accelerated atherosclerotic process. Novel stent technologies have been developed to improve the healing characteristics, but we will have to wait for the results of the Dual Antiplatelet Therapy Study, 32 if analysed according to stent type, to demonstrate that conceptual technological modifications have translated into a long-term decrease of thrombotic events.
Study limitations
While C-SES is no longer available, the two stents, through their biological diversity, define a 'wide therapeutic range'. As such they give a broader validity than a single stent type. Despite randomization, the groups were not matched exactly, most likely due to the play of chance, and two of the baseline characteristics affected were independent predictors of stent thrombosis; however, the imbalance was evenly distributed between the two groups, with moderate/ severe calcification more frequent in C-SES and ≥1 overlapping stent more frequent in E-ZES. Furthermore, the analysis determined the relation between DAPT use, DES type, and stent thrombosis, adjusting for potential confounders. The results are unlikely therefore to be biased by the imbalance. The mean lost to follow-up rate is ,5% (4.2%) in PROTECT and the mean incidence of the primary endpoint (definite or probable stent thrombosis) is 1.6%. Hence, one may argue that the lost to follow-up may have influenced the outcome. Baseline characteristics of the lost to follow-up group-with the exception of serum creatinine concentration-as well as the criteria identified as predictors of stent thrombosis did not differ between the E-ZES and C-SES groups ( Table 3 , Appendix) and thus it is unlikely that the lost to follow-up group influenced the endpoint of stent thrombosis in a differential manner. This analysis focuses on stent thrombosis and predictors of this event, and not on the clinical sequelae of stent thrombosis. Patients were not randomized to different durations of DAPT so a specific duration of DAPT use according to DES type cannot be derived. In the off-DAPT group, at 1 year a lower use of thienopyridine alone was observed in the C-SES group compared with the E-ZES group; however, the cumulative use of single antiplatelet therapy (aspirin alone or thienopyridine alone) was close to equal, and no difference in the incidence of stent thrombosis in the following 6-month time-window was observed. Lastly, the analysis is post hoc; even though the results are statistically sound due to the size of the trial and the broad inclusion criteria the conclusions have to be considered as hypothesis generating.
Conclusion
A strong interaction was observed between DES type and DAPT use, most likely prompted by the vascular healing response induced by the implanted DES system and determining a DES type-specific longterm need for DAPT adherence.
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